Latest Genetic resistance to malaria Stories
An international research team today reports the first-ever clinical trial demonstrating controlled malaria infection in an African nation in the modern era.
Single-cell genomics could provide new insight into the biology of Malaria parasites, including their virulence and levels of drug resistance, to ultimately improve treatment and control of the disease
Malaria is one of the major infectious diseases transmitted by mosquitos, with enormous impact on quality of life.
Recurrent episodes of malaria cause chronic inflammation in blood vessels that might predispose to future infections and may increase susceptibility to cardiovascular disease.
Human migrations—from the prehistoric epoch to the present day—have extended cultures across the globe.
A new, highly sensitive blood test that quickly detects even the lowest levels of malaria parasites in the body could make a dramatic difference in efforts to tackle the disease in the UK and across the world.
In malaria-endemic countries, 350 million people are predicted to be deficient in an enzyme that means they can suffer severe complications from taking primaquine, a key drug for treating relapsing malaria.
Their finding challenges the widely-accepted theory that Plasmodium falciparum, which causes the most lethal form of malaria, is the only malaria parasite capable of driving genome evolution in humans.